CSL Delnica

CSL Goodwill

Delisted·19. jun. 2026

Poslovni ugled od CSL (CSL.AX) na dan 17. avg. 2026 je 8,07 Mrd. USD. V prejšnjem letu je Poslovni ugled znašal 8,08 Mrd. USD — sprememba za −0,17 % (nižje).

Goodwill

8,07 Mrd.USD

YoY

−0,17%

Zadnja posodobitev:

Poslovni ugled od CSL je 2026 8,07 Mrd. USD. Poslovni ugled od CSL je bil 2025 8,08 Mrd. USD. Pada za −0,17% nižje v primerjavi s prejšnjim letom.
Access this data via the Eulerpool API

CSL Analiza delnic

Kaj dela CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL je eno najbolj priljubljenih podjetij na Eulopoolu.

Pogosto zastavljena vprašanja o delnici CSL

Poslovni ugled podjetja CSL znaša 8,07 Mrd. USD v letu 2026.

Poslovni ugled od CSL se je spremenil z 8,08 Mrd. USD na 8,07 Mrd. USD, kar predstavlja spremembo za −0,17 %. Vrednost je nižje kot v prejšnjem letu.

Na Eulopoolu najdete celovit zgodovinski razvoj Poslovni ugled CSL od leta 2006 – z letnimi vrednostmi, grafi in podrobno analizo.

Poslovni ugled je premija, ki se plača nad pošteno tržno vrednostjo pri prevzemu. Predstavlja neopredmeteno vrednost, kot so prepoznavnost blagovne znamke, odnosov s strankami in intelektualno lastnino.

Poslovni ugleds USD je ključni dejavnik za vlagatelje. Spremembe te metrike lahko signalizirajo izboljšanje ali poslabšanje temeljnih podatkov, kar neposredno vpliva na ceno delnice. Na Euloolu lahko spremljate Poslovni ugleds CSL v realnem času in zgodovinsko.

Access this data via the Eulerpool API

Bilanca stanja — CSL

Vse ključne metrike — CSL